<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2645281</article-id><article-id pub-id-type="doi">10.1371/annotation/8183042c-af40-4227-8a00-8f362de22220</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction: A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier</article-title><alt-title alt-title-type="running-head">Correction</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Karkan</surname><given-names>Delara</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pfeifer</surname><given-names>Cheryl</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vitalis</surname><given-names>Timothy Z.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Arthur</surname><given-names>Gavin</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ujiie</surname><given-names>Maki</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qingqi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Sam</given-names></name></contrib><contrib contrib-type="author"><name><surname>Koliatis</surname><given-names>Gerrasimo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gabathuler</surname><given-names>Reinhard</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jefferies</surname><given-names>Wilfred A.</given-names></name></contrib></contrib-group><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>17</day><month>7</month><year>2008</year></pub-date><volume>3</volume><issue>7</issue><elocation-id>10.1371/annotation/8183042c-af40-4227-8a00-8f362de22220</elocation-id><copyright-statement>Public Library of Science. This is an open-access article                distributed under the terms of the Creative Commons Attribution License, which                permits unrestricted use, distribution, and reproduction in any medium, provided the                original work is properly cited.</copyright-statement><copyright-year>2008</copyright-year><related-article related-article-type="corrected-article" vol="3" page="e2469" id="N0x1cffed0N0x20b9d40" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="18575595" ext-link-type="pubmed"><article-title>A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier</article-title></related-article></article-meta></front><body><p>The symbols in the first and second sentences of the legend to Figure 8 are incorrect. The correct Figure 8 legend should read: a) Percentage (%) survival of mice bearing intracranial ZR-75-1 mammary tumors and treated with p97-ADR conjugate SYN002 (5.5 mg/kg ADR, &#x025b2;-&#x025b2;), ADR (20mg/kg, &#x025a0;-&#x025a0;) or PBS (&#x025cf;-&#x025cf;). b) Percentage (%) survival of mice bearing intracranial C6 glioma tumors and treated with p97-ADR conjugate SYN018 (0.49mg/kg ADR, &#x025b2;-&#x025b2;) or PBS (&#x025cf;-&#x025cf;). </p></body></article>